These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16766543)

  • 21. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
    Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
    Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
    Papademetriou V; Farsang C; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A;
    J Am Coll Cardiol; 2004 Sep; 44(6):1175-80. PubMed ID: 15364316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly.
    Lundkvist J; Ekman M; Kartman B; Carlsson J; Jönsson L; Lithell H
    J Hum Hypertens; 2005 Jul; 19(7):569-76. PubMed ID: 15800664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.
    Suzuki H; Kanno Y;
    Hypertens Res; 2005 Apr; 28(4):307-14. PubMed ID: 16138560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
    Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
    Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
    Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
    J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
    Shigenaga A; Tamura K; Dejima T; Ozawa M; Wakui H; Masuda S; Azuma K; Tsurumi-Ikeya Y; Mitsuhashi H; Okano Y; Kokuho T; Sugano T; Ishigami T; Toya Y; Uchino K; Tokita Y; Umemura S
    Nephron Clin Pract; 2009; 112(1):c31-40. PubMed ID: 19342867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy).
    Sugiura R; Ogawa H; Oka T; Koyanagi R; Hagiwara N;
    Am J Cardiol; 2012 Feb; 109(4):576-80. PubMed ID: 22100194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
    Solomon SD; Dobson J; Pocock S; Skali H; McMurray JJ; Granger CB; Yusuf S; Swedberg K; Young JB; Michelson EL; Pfeffer MA;
    Circulation; 2007 Sep; 116(13):1482-7. PubMed ID: 17724259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
    Nakao K; Hirata M; Oba K; Yasuno S; Ueshima K; Fujimoto A; Ogihara T; Saruta T;
    Hypertens Res; 2010 Jun; 33(6):600-6. PubMed ID: 20379187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.
    Castagno D; Skali H; Takeuchi M; Swedberg K; Yusuf S; Granger CB; Michelson EL; Pfeffer MA; McMurray JJ; Solomon SD;
    J Am Coll Cardiol; 2012 May; 59(20):1785-95. PubMed ID: 22575317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients.
    Phakdeekitcharoen B; Leelasa-nguan P
    Am J Kidney Dis; 2004 Oct; 44(4):738-46. PubMed ID: 15384026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristics.
    Hansson L; Lithell H; Skoog I; Baro F; Bánki CM; Breteler M; Castaigne A; Correia M; Degaute JP; Elmfeldt D; Engedal K; Farsang C; Ferro J; Hachinski V; Hofman A; James OF; Krisin E; Leeman M; de Leeuw PW; Leys D; Lobo A; Nordby G; Olofsson B; Opolski G; Prince M; Reischies FM
    Blood Press; 2000; 9(2-3):146-51. PubMed ID: 10855739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
    Desai AS; Swedberg K; McMurray JJ; Granger CB; Yusuf S; Young JB; Dunlap ME; Solomon SD; Hainer JW; Olofsson B; Michelson EL; Pfeffer MA;
    J Am Coll Cardiol; 2007 Nov; 50(20):1959-66. PubMed ID: 17996561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.